Safinamide Mesylate

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Safinamide mesylate is the methanesulfonic acid form of its active component safinamide, a selective and reversible monoamine oxidase B (MAO-B) inhibitor with the value of 50% inhibition concentration IC50 of 98 nM. Having been used for the treatment of Parkinson’s disease (PD), safinamide potently modulates dopamine (DA), a substrate of MAO-B, suppressing DA uptake and reversibly binds to MAO-B blocking the function of MAO-B, which lead to the relief of PD symptoms. Besides MAO-B inhibition, safinamide exhibits novel anticonvulsant activities, including sodium channel blockade, calcium channel blockade and glutamate release inhibition, with values of IC50 of 8.2 μM, 31.5 μM and >56.4 μM respectively.
- Properties
  - Alternative Name
    
    FCE-28073, PNU 151774E, methanesulfonate; (2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid
    
    CAS Number
    
    202825-46-5
    
    Molecular Formula
    
    C17H19FN2O2·CH4O3S
    
    Molecular Weight
    
    398.45
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    ≥10.08 mg/mL in EtOH with gentle warming and ultrasonic; ≥16.1 mg/mL in DMSO; ≥84.6 mg/mL in H2O
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only